NCT02976831View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability and Pharmacokinetics and Pharmacodynamics of AZD0284 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

83

Participants

Timeline

Start Date

December 9, 2016

Primary Completion Date

May 30, 2017

Study Completion Date

May 30, 2017

Conditions

Plaque Psoriasis Vulgaris

Interventions

DRUG

AZD0284

Oral solution, concentration: 2 mg/mL and 15 mg/mL

DRUG

Placebo

Placebo matching AZD0284 in the form of an oral solution with water.

Trial Locations (1)

HA1 3UJ

Research Site, London

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Parexel

INDUSTRY

lead

AstraZeneca

INDUSTRY